Literature DB >> 12842283

Neuroprotection of naloxone against ischemic injury in rats: role of mu receptor antagonism.

Su-Lan Liao1, Wen-Yin Chen, Shue-Ling Raung, Chun-Jung Chen.   

Abstract

Naloxone has been advanced as a potential neuroprotectant against ischemic injury. This study examined the involvement of classical opioid receptors in the reduction of middle cerebral arterial ligation-induced cortical infarction in rats. The infarct volume was significantly reduced after infusion of (-)-naloxone, but not its inert stereoisomer (+)-naloxone. Beta-funaltrexamine (beta-FNA), a mu opioid antagonist, also reduced ischemic infarct volume. Both (-)-naloxone and beta-FNA attenuated cerebral ischemia/reperfusion (I/R)-induced increases in neutrophil-associated myeloperoxidase activity and chemokine mRNA expression, including macrophage inflammatory protein-1 alpha and -2. However, (-)-naloxone and beta-FNA failed to decrease cerebral I/R-induced brain edema. The findings suggest that naloxone, acting through a blockade of mu opioid receptor activation, is beneficial to cerebral I/R insult in terms of reducing brain infarction, neutrophil accumulation, and chemokine expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842283     DOI: 10.1016/s0304-3940(03)00540-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

2.  Morphine preconditioning protects against LPS-induced neuroinflammation and memory deficit.

Authors:  Farzaneh Rostami; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

3.  Delta-opioid receptor activation prolongs respiratory motor output during oxygen-glucose deprivation in neonatal rat spinal cord in vitro.

Authors:  S M F Turner; S M Johnson
Journal:  Neuroscience       Date:  2011-05-06       Impact factor: 3.590

4.  DOR activation inhibits anoxic/ischemic Na+ influx through Na+ channels via PKC mechanisms in the cortex.

Authors:  Dongman Chao; Xiaozhou He; Yilin Yang; Alia Bazzy-Asaad; Lawrence H Lazarus; Gianfranco Balboni; Dong H Kim; Ying Xia
Journal:  Exp Neurol       Date:  2012-05-15       Impact factor: 5.330

Review 5.  Opioid antagonists as potential therapeutics for ischemic stroke.

Authors:  Nadia Peyravian; Emre Dikici; Sapna Deo; Michal Toborek; Sylvia Daunert
Journal:  Prog Neurobiol       Date:  2019-08-06       Impact factor: 11.685

6.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

7.  (+)-Naloxone blocks Toll-like receptor 4 to ameliorate deleterious effects of stress on male mouse behaviors.

Authors:  Eva M Medina-Rodriguez; Kenner C Rice; Eléonore Beurel; Richard S Jope
Journal:  Brain Behav Immun       Date:  2020-08-26       Impact factor: 7.217

Review 8.  The mechanisms of brain ischemic insult and potential protective interventions.

Authors:  Zhao-Hui Guo; Feng Li; Wei-Zhi Wang
Journal:  Neurosci Bull       Date:  2009-06       Impact factor: 5.203

9.  The opioid receptor antagonist, naloxone, protects spinal motor neurons in a murine model of alphavirus encephalomyelitis.

Authors:  Natalie A Prow; David N Irani
Journal:  Exp Neurol       Date:  2007-03-23       Impact factor: 5.330

10.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.